Cellular mechanisms of tumour suppression by the retinoblastoma gene

Nature Reviews Cancer

Volumn 8, Issue 9, 2008, Pages 671-682

  Burkhart, Deborah L ^a   Sage, Julien ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOBLASTOMA PROTEIN;

ANGIOGENESIS; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CELL CYCLE PROGRESSION; CELL DEATH; CELL FUNCTION; CELL TYPE; DNA REPAIR; EARLY CANCER; GENE INACTIVATION; HUMAN; MOUSE; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; STEM CELL; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL CYCLE; CELL DIFFERENTIATION; GENES, RETINOBLASTOMA; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; RNA PROCESSING, POST-TRANSCRIPTIONAL; STEM CELLS;

EID: 50149120366     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2399     Document Type: Review

References (219)

1. Riley, D. J., Lee, E. Y. & Lee, W. H. The retinoblastoma protein: more than a tumor suppressor. Annu. Rev. Cell Biol. 10, 1-29 (1994).
2. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell 81, 323-330 (1995).
3. Zheng, L. & Lee, W. H. The retinoblastoma gene: a prototypic and multifunctional tumor suppressor. Exp. Cell Res. 264, 2-18 (2001).
4. Dannenberg, J. H. & te Riele, H. P. The retinoblastoma gene family in cell cycle regulation and suppression of tumorigenesis. Results Probl. Cell Differ. 42, 183-225 (2006).
5. Ji, P. et al. An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. Mol. Cell 16, 47-58 (2004).
6. Binne, U. K. et al. Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nature Cell Biol. 9, 225-232 (2007). References 5 and 6 demonstrate that the role of RB in cell cycle control is not solely mediated through its interactions with E2F transcription factors.
7. Wikenheiser-Brokamp, K. A. Retinoblastoma family proteins: insights gained through genetic manipulation of mice. Cell Mol. Life Sci. 63, 767-780 (2006).
8. Cobrinik, D. Pocket proteins and cell cycle control. Oncogene 24, 2796-2809 (2005).
9. Claudio, P. P., Tonini, T. & Giordano, A. The retinoblastoma family: twins or distant cousins? Genome Biol. 3, reviews3012 (2002).
10. Classon, M. & Dyson, N. p107 and p130: versatile proteins with interesting pockets. Exp. Cell Res. 264, 135-147. (2001).
11. Morris, E. J. & Dyson, N. J. Retinoblastoma protein partners. Adv. Cancer Res. 82, 1-54 (2001).
12. Macaluso, M., Montanari, M. & Giordano, A. Rb family proteins as modulators of gene expression and new aspects regarding the interaction with chromatin remodeling enzymes. Oncogene 25, 5263-5267 (2006).
13. Gonzalo, S. & Blasco, M. A. Role of Rb family in the epigenetic definition of chromatin. Cell Cycle 4, 752-755 (2005).
14. Brehm, A. & Kouzarides, T. Retinoblastoma protein meets chromatin. Trends Biochem. Sci. 24, 142-145 (1999).
15. Knudson, A. G., Jr. Genetic predisposition to cancer. Cancer Detect Prev. 7, 1-8 (1984).
16. Corson, T. W. & Gallie, B. L. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer 46, 617-634 (2007).
17. Dimaras, H. et al. Loss of RB1 induces nonproliferative retinoma; increasing genomic instability correlates with progression to retinoblastoma. Hum. Mol. Genet. (2008).
18. Friend, S. H. et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323, 643-646 (1986).
19. Bookstein, R. & Lee, W. H. Molecular genetics of the retinoblastoma suppressor gene. Crit. Rev. Oncog. 2, 211-227 (1991).
20. Deshpande, A. & Hinds, P. W. The retinoblastoma protein in osteoblast differentiation and osteosarcoma. Curr. Mol. Med. 6, 809-817 (2006).
21. Doorbar, J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. 110, 525-541 (2006).
22. Perez-Ordonez, B., Beauchemin, M. & Jordan, R. C. Molecular biology of squamous cell carcinoma of the head and neck. J. Clin. Pathol. 59, 445-453 (2006).
23. Munakata, T. et al. Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog. 3, 1335-1347 (2007).
24. Meuwissen, R. et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4, 181-189 (2003). Describes a mouse model of human SCLC, the only adult tumour type in which loss of RB function occurs in most, if not all cases.
25. Ranade, K. et al. Mutations associated with familial melanoma impair p16INK4 function. Nature Genet. 10, 114-116 (1995).
26. Zuo, L. et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature Genet. 12, 97-99 (1996).
27. Berman, H. et al. Genetic and epigenetic changes in mammary epithelial cells identify a subpopulation of cells involved in early carcinogenesis. Cold Spring Harb. Symp. Quant. Biol. 70, 317-327 (2005).
28. Smith, E. J., Leone, G., DeGregori, J., Jakoi, L. & Nevins, J. R. The accumulation of an E2F-p130 transcriptional repressor distinguishes a G0 cell state from a G1 cell state. Mol. Cell. Biol. 16, 6965-6976 (1996).
29. Balciunaite, E. et al. Pocket protein complexes are recruited to distinct targets in quiescent and proliferating cells. Mol. Cell. Biol. 25, 8166-8178 (2005).
30. Takahashi, Y., Rayman, J. B. & Dynlacht, B. D. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev. 14, 804-816 (2000).
31. Sage, J., Miller, A. L., Perez-Mancera, P. A., Wysocki, J. M. & Jacks, T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 424, 223-228 (2003).
32. Daria, D. et al. The retinoblastoma tumor suppressor is a critical intrinsic regulator for hematopoietic stem and progenitor cells under stress. Blood 111, 1894-1902 (2008).
33. Walkley, C. R. & Orkin, S. H. Rb is dispensable for self-renewal and multilineage differentiation of adult hematopoietic stem cells. Proc. Natl Acad. Sci. USA 103, 9057-9062 (2006).
34. Walkley, C. R., Shea, J. M., Sims, N. A., Purton, L. E. & Orkin, S. H. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 129, 1081-1095 (2007).
35. Ruiz, S. et al. Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development 131, 2737-2748 (2004).
36. Wildwater, M. et al. The RETINOBLASTOMA-RELATED gene regulates stem cell maintenance in Arabidopsis roots. Cell 123, 1337-1349 (2005). Provides the first description of a role for RB in maintaining a stem cell pool in vivo.
37. Wier, M. L. & Scott, R. E. Regulation of the terminal event in cellular differentiation: biological mechanisms of the loss of proliferative potential. J. Cell Biol. 102, 1955-1964 (1986).
38. Peacocke, M. & Campisi, J. Cellular senescence: a reflection of normal growth control, differentiation, or aging? J. Cell Biochem. 45, 147-155 (1991).
39. Beausejour, C. M. et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 22, 4212-4222 (2003).
40. Narita, M. et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703-716 (2003).
41. Ferreira, R., Naguibneva, I., Pritchard, L. L., Ait-Si-Ali, S. & Harel-Bellan, A. The Rb/chromatin connection and epigenetic control: opinion. Oncogene 20, 3128-3133. (2001).
42. Skapek, S. X., Pan, Y. R. & Lee, E. Y. Regulation of cell lineage specification by the retinoblastoma tumor suppressor. Oncogene 25, 5268-5276 (2006).
43. Mayhew, C. N. et al. Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidy. Cancer Res. 65, 4568-4577 (2005).
44. Slack, R. S., El-Bizri, H., Wong, J., Belliveau, D. J. & Miller, F. D. A critical temporal requirement for the retinoblastoma protein family during neuronal determination. J. Cell Biol. 140, 1497-1509 (1998).
45. Camarda, G. et al. A pRb-independent mechanism preserves the postmitotic state in terminally differentiated skeletal muscle cells. J. Cell Biol. 167, 417-423 (2004).
46. Huh, M. S., Parker, M. H., Scime, A., Parks, R. & Rudnicki, M. A. Rb is required for progression through myogenic differentiation but not maintenance of terminal differentiation. J. Cell Biol. 166, 865-876 (2004).
47. Blais, A., van Oevelen, C. J., Margueron, R., Acosta-Alvear, D. & Dynlacht, B. D. Retinoblastoma tumor suppressor protein-dependent methylation of histone H3 lysine 27 is associated with irreversible cell cycle exit. J. Cell Biol. 179, 1399-1412 (2007).
48. Weber, T. et al. Rapid cell-cycle reentry and cell death after acute inactivation of the retinoblastoma gene product in postnatal cochlear hair cells. Proc. Natl Acad. Sci. USA 105, 781-785 (2008).
49. Ferguson, K. L. et al. Telencephalon-specific Rb knockouts reveal enhanced neurogenesis, survival and abnormal cortical development. EMBO J. 21, 3337-3346. (2002).
50. Chen, D. et al. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma. Cancer Cell 5, 539-551 (2004).
51. MacPherson, D. et al. Cell type-specific effects of Rb deletion in the murine retina. Genes Dev. 18, 1681-1694 (2004).
52. Ajioka, I. et al. Differentiated horizontal interneurons clonally expand to form metastatic retinoblastoma in mice. Cell 131, 378-390 (2007). Describes the first example of a fully differentiated cell (a neuron) that re-enters the cell cycle to initiate cancer.
53. Callaghan, D. A. et al. Neural precursor cells differentiating in the absence of Rb exhibit delayed terminal mitosis and deregulated E2F 1 and 3 activity. Dev. Biol. 207, 257-270 (1999).
54. Ferguson, K. L. & Slack, R. S. The Rb pathway in neurogenesis. Neuroreport 12, A55-A62 (2001).
55. Zhang, J. et al. Rb regulates proliferation and rod photoreceptor development in the mouse retina. Nature Genet. 36, 351-360 (2004).
56. Dyer, M. A. & Bremner, R. The search for the retinoblastoma cell of origin. Nature Rev. Cancer 5, 91-101 (2005).
57. Pacal, M. & Bremner, R. Insights from animal models on the origins and progression of retinoblastoma. Curr. Mol. Med. 6, 759-781 (2006). References 50, 51 and 55, and the two reviews 56 and 57 describe the first breedable mouse models of retinoblastoma and investigate the mechanisms of tumorigenesis in the retina.
58. Khidr, L. & Chen, P. L. RB, the conductor that orchestrates life, death and differentiation. Oncogene 25, 5210-5219 (2006).
59. Nguyen, D. X. & McCance, D. J. Role of the retinoblastoma tumor suppressor protein in cellular differentiation. J. Cell Biochem. 94, 870-879 (2005).
60. Thomas, D. M., Yang, H. S., Alexander, K. & Hinds, P. W. Role of the retinoblastoma protein in differentiation and senescence. Cancer Biol. Ther. 2, 124-130 (2003).
61. Classon, M. & Harlow, E. The retinoblastoma tumour suppressor in development and cancer. Nature Rev. Cancer 2, 910-917 (2002).
62. Iavarone, A. et al. Retinoblastoma promotes definitive erythropoiesis by repressing Id2 in fetal liver macrophages. Nature 432, 1040-1045 (2004).
63. Lasorella, A., Noseda, M., Beyna, M., Yokota, Y. & Iavarone, A. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 407, 592-598 (2000). Describes a crucial link between MYC signalling and RB function, and provides mechanistic evidence that the interactions between ID2 and RB might regulate the proliferation and differentiation of cells.
64. Miyake, S. et al. Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle. Mol. Cell. Biol. 20, 8889-8902 (2000).
65. MacLellan, W. R., Xiao, G., Abdellatif, M. & Schneider, M. D. A novel Rb- and p300-binding protein inhibits transactivation by MyoD. Mol. Cell. Biol. 20, 8903-8915 (2000).
66. Benevolenskaya, E. V., Murray, H. L., Branton, P., Young, R. A. & Kaelin, W. G., Jr. Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol. Cell 18, 623-635 (2005).
67. Krutzfeldt, M. et al. Selective ablation of retinoblastoma protein function by the RET finger protein. Mol. Cell 18, 213-224 (2005).
68. Chen, D. et al. Rb-mediated neuronal differentiation through cell-cycle-independent regulation of E2f3a. PLoS Biol. 5, e179 (2007).
69. McClellan, K. A. et al. Unique requirement for Rb/E2F3 in neuronal migration: evidence for cell cycle-independent functions. Mol. Cell. Biol. 27, 4825-4843 (2007). References 68 and 69 describe a novel function of RB in controlling cell migration, distinct from its role in the cell cycle, and show that E2F transcription factors might mediate this novel function of RB in vivo.
70. Sidle, A. et al. Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation. Crit. Rev. Biochem. Mol. Biol. 31, 237-271 (1996).
71. Sellers, W. R. et al. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev. 12, 95-106 (1998). A classical example dissecting the mechanisms of retinoblastoma development by studying various mutants of RB; these observations highlight the fact that a pro-differentiation activity of RB that is independent of E2F acts as a tumour suppressor mechanism.
72. Thomas, D. M. et al. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol. Cell 8, 303-316 (2001).
73. Kleinerman, R. A. et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J. Clin. Oncol. 23, 2272-2279 (2005).
74. Tsai, K. Y. et al. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol. Cell 2, 293-304 (1998).
75. Macleod, K. F., Hu, Y. & Jacks, T. Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO J. 15, 6178-6188 (1996).
76. Inoue, Y., Kitagawa, M. & Taya, Y. Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB and E2F-1 after DNA damage. EMBO J. 26, 2083-2093 (2007).
77. Markham, D., Munro, S., Soloway, J., O'Connor, D. P. & La Thangue, N. B. DNA-damage-responsive acetylation of pRb regulates binding to E2F-1. EMBO Rep. 7, 192-198 (2006).
78. Dick, F. A. Structure-function analysis of the retinoblastoma tumor suppressor protein - is the whole a sum of its parts? Cell Div. 2, 26 (2007).
79. Ziebold, U., Reza, T., Caron, A. & Lees, J. A. E2F3 contributes both to the inappropriate proliferation and to the apoptosis arising in Rb mutant embryos. Genes Dev. 15, 386-391 (2001).
80. Saavedra, H. I. et al. Specificity of E2F1, E2F2, and E2F3 in mediating phenotypes induced by loss of Rb. Cell Growth Differ. 13, 215-225 (2002).
81. Bosco, E. E. & Knudsen, E. S. Differential role of RB in response to UV and IR damage. Nucleic Acids Res. 33, 1581-1592 (2005).
82. Prost, S., Lu, P., Caldwell, H. & Harrison, D. E2F regulates DDB2: consequences for DNA repair in Rb-deficient cells. Oncogene 26, 3572-3581 (2007).
83. Billecke, C. A. et al. Lack of functional pRb results in attenuated recovery of mRNA synthesis and increased apoptosis following UV radiation in human breast cancer cells. Oncogene 21, 4481-4489 (2002).
84. Bosco, E. E. et al. RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Res. 32, 25-34 (2004).
85. Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352-1355 (2008).
86. Jiang, Z. & Zacksenhaus, E. Activation of retinoblastoma protein in mammary gland leads to ductal growth suppression, precocious differentiation, and adenocarcinoma. J. Cell Biol. 156, 185-198 (2002).
87. Symonds, H. et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78, 703-711 (1994).
88. Chau, B. N. & Wang, J. Y. Coordinated regulation of life and death by RB. Nature Rev. Cancer 3, 130-138 (2003).
89. Borges, H. L., Hunton, I. C. & Wang, J. Y. Reduction of apoptosis in Rb-deficient embryos via Abl knockout. Oncogene 26, 3868-3877 (2007).
90. Moroni, M. C. et al. Apaf-1 is a transcriptional target for E2F and p53. Nature Cell Biol. 3, 552-558 (2001).
91. Simpson, M. T. et al. Caspase 3 deficiency rescues peripheral nervous system defect in retinoblastoma nullizygous mice. J. Neurosci. 21, 7089-7098 (2001).
92. Seifried, L. A. et al. pRB-E2F1 complexes are resistant to adenovirus E1A-mediated disruption. J. Virol. 82, 4511-4520 (2008).
93. Weinstein, I. B. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 21, 857-864 (2000).
94. Pickering, M. T. & Kowalik, T. F. Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation. Oncogene 25, 746-755 (2006).
95. Mathew, R., Karantza-Wadsworth, V. & White, E. Role of autophagy in cancer. Nature Rev. Cancer 7, 961-967 (2007).
96. Jin, S. & White, E. Tumor suppression by autophagy through the management of metabolic stress. Autophagy 4, 563-566 (2008).
97. Tracy, K. et al. BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy. Mol. Cell. Biol. 27, 6229-6242 (2007).
98. Polager, S., Ofir, M. & Ginsberg, D. E2F1 regulates autophagy and the transcription of autophagy genes. Oncogene 14 April 2008 (doi:10.1038/onc.2008.117).
99. Sanseverino, F. et al. pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade. Cancer Biol. Ther. 5, 84-88 (2006).
100. Sell, S. Leukemia: stem cells, maturation arrest, and differentiation therapy. Stem Cell Rev. 1, 197-205 (2005).
101. Foijer, F., Wolthuis, R. M., Doodeman, V., Medema, R. H. & te Riele, H. Mitogen requirement for cell cycle progression in the absence of pocket protein activity. Cancer Cell 8, 455-466 (2005).
102. Eguchi, T., Takaki, T., Itadani, H. & Kotani, H. RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene. Oncogene 26, 509-520 (2007).
103. Kennedy, B. K., Barbie, D. A., Classon, M., Dyson, N. & Harlow, E. Nuclear organization of DNA replication in primary mammalian cells. Genes Dev. 14, 2855-2868 (2000).
104. Zheng, L., Flesken-Nikitin, A., Chen, P. L. & Lee, W. H. Deficiency of Retinoblastoma gene in mouse embryonic stem cells leads to genetic instability. Cancer Res. 62, 2498-2502 (2002).
105. Zheng, L. & Lee, W. H. Retinoblastoma tumor suppressor and genome stability. Adv. Cancer Res. 85, 13-50 (2002).
106. Srinivasan, S. V., Mayhew, C. N., Schwemberger, S., Zagorski, W. & Knudsen, E. S. RB loss promotes aberrant ploidy by deregulating levels and activity of DNA replication factors. J. Biol. Chem. 282, 23867-23877 (2007).
107. Hernando, E. et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430, 797-802 (2004).
108. Sotillo, R. et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11, 9-23 (2007).
109. Isaac, C. E. et al. The retinoblastoma protein regulates pericentric heterochromatin. Mol. Cell. Biol. 26, 3659-3671 (2006). Describes one of the first in vivo models to use a knock-in mouse to understand the cellular function of individual protein residues of RB.
110. Gonzalo, S. et al. Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nature Cell Biol. 7, 420-428 (2005).
111. Knudsen, E. S., Sexton, C. R. & Mayhew, C. N. Role of the retinoblastoma tumor suppressor in the maintenance of genome integrity. Curr. Mol. Med. 6, 749-757 (2006).
112. McCabe, M. T., Davis, J. N. & Day, M. L. Regulation of DNA methyltransferase 1 by the pRb/E2F1 pathway. Cancer Res. 65, 3624-3632 (2005).
113. Iovino, F., Lentini, L., Amato, A. & Di Leonardo, A. RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. Mol. Cancer 5, 38 (2006).
114. Meraldi, P., Lukas, J., Fry, A. M., Bartek, J. & Nigg, E. A. Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A. Nature Cell Biol. 1, 88-93 (1999).
115. Longworth, M. S., Herr, A., Ji, J. Y. & Dyson, N. J. RBF1 promotes chromatin condensation through a conserved interaction with the Condensin II protein dCAP-D3. Genes Dev. 22, 1011-1024 (2008).
116. Harrington, E. A., Bruce, J. L., Harlow, E. & Dyson, N. pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc. Natl Acad. Sci. USA 95, 11945-11950 (1998).
117. Siddiqui, H., Fox, S. R., Gunawardena, R. W. & Knudsen, E. S. Loss of RB compromises specific heterochromatin modifications and modulates HP1α dynamics. J. Cell Physiol. 211, 131-137 (2007).
118. Robertson, K. D. et al. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nature Genet. 25, 338-342 (2000).
119. Lund, A. H. & van Lohuizen, M. Epigenetics and cancer. Genes Dev. 18, 2315-2335 (2004).
120. McCabe, D. C. & Caudill, M. A. DNA methylation, genomic silencing, and links to nutrition and cancer. Nutr. Rev. 63, 183-195 (2005).
121. Sage, J. Making young tumors old: a new weapon against cancer? Sci. Aging Knowledge Environ. pe25 (2005).
122. Collado, M., Blasco, M. A. & Serrano, M. Cellular senescence in cancer and aging. Cell 130, 223-233 (2007).
123. Courtois-Cox, S., Jones, S. L. & Cichowski, K. Many roads lead to oncogene-induced senescence. Oncogene 27, 2801-2089 (2008).
124. Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665 (2005).
125. Garcia-Cao, M., Gonzalo, S., Dean, D. & Blasco, M. A. A role for the Rb family of proteins in controlling telomere length. Nature Genet. 32, 415-419 (2002).
126. Kong, L. J., Meloni, A. R. & Nevins, J. R. The Rb-related p130 protein controls telomere lengthening through an interaction with a Rad50-interacting protein, RINT-1. Mol. Cell 22, 63-71 (2006).
127. Wei, W., Herbig, U., Wei, S., Dutriaux, A. & Sedivy, J. M. Loss of retinoblastoma but not p16 function allows bypass of replicative senescence in human fibroblasts. EMBO Rep. 4, 1061-1066 (2003).
128. Young, A. P. et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nature Cell Biol. 10, 361-369 (2008).
129. Alexander, K. & Hinds, P. W. Requirement for p27(KIP1) in retinoblastoma protein-mediated senescence. Mol. Cell. Biol. 21, 3616-3631 (2001).
130. Gabellini, C., Del Bufalo, D. & Zupi, G. Involvement of RB gene family in tumor angiogenesis. Oncogene 25, 5326-5332 (2006).
131. Chien, W. M. et al. Differential gene expression of p27Kip1 and Rb knockout pituitary tumors associated with altered growth and angiogenesis. Cell Cycle 6, 750-757 (2007).
132. Lasorella, A., Rothschild, G., Yokota, Y., Russell, R. G. & Iavarone, A. Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice. Mol. Cell. Biol. 25, 3563-3574 (2005).
133. Ruzinova, M. B. & Benezra, R. Id proteins in development, cell cycle and cancer. Trends Cell Biol. 13, 410-418 (2003).
134. Benezra, R., Rafii, S. & Lyden, D. The Id proteins and angiogenesis. Oncogene 20, 8334-8341 (2001).
135. Dasgupta, P. et al. Disruption of the Rb-Raf-1 interaction inhibits tumor growth and angiogenesis. Mol. Cell. Biol. 24, 9527-9541 (2004).
136. Martinez-Cruz, A. B. et al. Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res. 68, 683-692 (2008).
137. Hui, A. M., Li, X., Makuuchi, M., Takayama, T. & Kubota, K. Over-expression and lack of retinoblastoma protein are associated with tumor progression and metastasis in hepatocellular carcinoma. Int. J. Cancer 84, 604-608 (1999).
138. Gauthier, M. L. et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 12, 479-491 (2007).
139. Singh, B., Berry, J. A., Shoher, A., Ramakrishnan, V. & Lucci, A. COX-2 overexpression increases motility and invasion of breast cancer cells. Int. J. Oncol. 26, 1393-1399 (2005).
140. Tsujii, M., Kawano, S. & DuBois, R. N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl Acad. Sci. USA 94, 3336-3340 (1997).
141. Ferguson, K. L. et al. A cell-autonomous requirement for the cell cycle regulatory protein, Rb, in neuronal migration. EMBO J. 24, 4381-4391 (2005).
142. Ziebold, U., Lee, E. Y., Bronson, R. T. & Lees, J. A. E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas. Mol. Cell. Biol. 23, 6542-6552 (2003).
143. Stanelle, J., Stiewe, T., Theseling, C. C., Peter, M. & Putzer, B. M. Gene expression changes in response to E2F1 activation. Nucleic Acids Res. 30, 1859-1867 (2002).
144. Yoon, S. O., Shin, S. & Mercurio, A. M. Ras stimulation of E2F activity and a consequent E2F regulation of integrin alpha6beta4 promote the invasion of breast carcinoma cells. Cancer Res. 66, 6288-6295 (2006).
145. Zhang, S. Y., Liu, S. C., Johnson, D. G. & Klein-Szanto, A. J. E2F-1 gene transfer enhances invasiveness of human head and neck carcinoma cell lines. Cancer Res. 60, 5972-5976 (2000).
146. Calzone, L., Gelay, A., Zinovyev, A., Radvanyl, F. & Barillot, E. A comprehensive modular map of molecular interactions in RB/E2F pathway. Mol. Syst. Biol. 4, 173 (2008).
147. Marino, S., Vooijs, M., van Der Gulden, H., Jonkers, J. & Berns, A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 14, 994-1004. (2000).
148. Zhou, Z., Flesken-Nikitin, A. & Nikitin, A. Y. Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. Cancer Res. 67, 5683-5690 (2007).
149. Flesken-Nikitin, A., Choi, K. C., Eng., J. P., Shmidt, E. N. & Nikitin, A. Y. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. 63, 3459-3463 (2003).
150. Dannenberg, J. H., Schuijff, L., Dekker, M., van der Valk, M. & te Riele, H. Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Genes Dev. 18, 2952-2962 (2004).
151. Sotillo, R. et al. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J. 20, 6637-6647 (2001).
152. Rane, S. G., Cosenza, S. C., Mettus, R. V. & Reddy, E. P. Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol. Cell. Biol. 22, 644-656 (2002).
153. Ortega, S., Malumbres, M. & Barbacid, M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta 1602, 73-87 (2002).
154. Yin, C., Knudson, C. M., Korsmeyer, S. J. & Van Dyke, T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385, 637-640 (1997).
155. Pan, H. et al. Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. Mol. Cell 2, 283-292 (1998).
156. Lu, X. et al. Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability. Mol. Cell. Biol. 21, 6017-6030 (2001).
157. Xiao, A., Wu, H., Pandolfi, P. P., Louis, D. N. & Van Dyke, T. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell 1, 157-168 (2002).
158. Simin, K. et al. pRb inactivation in mammary cells reveals common mechanisms for tumor initiation and progression in divergent epithelia. PLoS Biol. 2, E22 (2004).
159. Hill, R., Song, Y., Cardiff, R. D. & Van Dyke, T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123, 1001-1011 (2005).
160. Hill, R., Song, Y., Cardiff, R. D. & Van Dyke, T. Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. Cancer Res. 65, 10243-10254 (2005).
161. Simin, K. et al. Deciphering cancer complexities in genetically engineered mice. Cold Spring Harb. Symp. Quant. Biol. 70, 283-290 (2005). References 154-161 illustrate the efforts from the Van Dyke group to study the role of the entire Rb family in preventing cancer initiation in different cell types in mice.
162. Frese, K. K. & Tuveson, D. A. Maximizing mouse cancer models. Nature Rev. Cancer 7, 645-658 (2007).
163. +/- mice. Proc. Natl Acad. Sci. USA 96, 3916-3921 (1999).
164. Zhou, Z. et al. Suppression of melanotroph carcinogenesis leads to accelerated progression of pituitary anterior lobe tumors and medullary thyroid carcinomas in Rb+/- mice. Cancer Res. 65, 787-796 (2005).
165. Zwijsen, R. M. CDK-independent activation of estrogen receptor by cyclin D1. Cell 88, 405-415 (1997).
166. Liu, F. Smad3 phosphorylation by cyclin-dependent kinases. Cytokine Growth Factor Rev. 17, 9-17 (2006).
167. Kaye, F. J. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene 21, 6908-6914 (2002).
168. Trimarchi, J. M. & Lees, J. A. Sibling rivalry in the E2F family. Nature Rev. Mol. Cell Biol. 3, 11-20 (2002).
169. Smith, E. J., Leone, G. & Nevins, J. R. Distinct mechanisms control the accumulation of the Rb-related p107 and p130 proteins during cell growth. Cell Growth Differ. 9, 297-303 (1998).
170. Tedesco, D., Lukas, J. & Reed, S. I. The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). Genes Dev. 16, 2946-2957 (2002).
171. +/- mice. Nature Genet. 18, 360-364 (1998).
172. Feber, A. et al. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 23, 1627-1630 (2004).
173. Grasemann, C. et al. Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene 24, 6441-6449 (2005).
174. Lee, C., Chang, J. H., Lee, H. S. & Cho, Y. Structural basis for the recognition of the E2F transactivation domain by the retinoblastoma tumor suppressor. Genes Dev. 16, 3199-3212 (2002).
175. Kim, H. Y., Ahn, B. Y. & Cho, Y. Structural basis for the inactivation of retinoblastoma tumor suppressor by SV40 large T antigen. EMBO J. 20, 295-304 (2001).
176. Lee, J. O., Russo, A. A. & Pavletich, N. P. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 391, 859-865 (1998).
177. Julian, L. M., Palander, O., Seifried, L. A., Foster, J. E. & Dick, F. A. Characterization of an E2F1-specific binding domain in pRB and its implications for apoptotic regulation. Oncogene 27, 1572-1579 (2008).
178. Chan, H. M., Krstic-Demonacos, M., Smith, L., Demonacos, C. & La Thangue, N. B. Acetylation control of the retinoblastoma tumour-suppressor protein. Nature Cell Biol. 3, 667-674 (2001).
179. Nguyen, D. X., Baglia, L. A., Huang, S. M., Baker, C. M. & McCance, D. J. Acetylation regulates the differentiation-specific functions of the retinoblastoma protein. EMBO J. 23, 1609-1618 (2004).
180. Ledl, A., Schmidt, D. & Muller, S. Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor. Oncogene 24, 3810-3818 (2005).
181. Borges, H. L. et al. Tumor promotion by caspase-resistant retinoblastoma protein. Proc. Natl Acad. Sci. USA 102, 15587-15592 (2005).
182. Wikenheiser-Brokamp, K. A. Retinoblastoma regulatory pathway in lung cancer. Curr. Mol. Med. 6, 783-793 (2006).
183. Kaye, F. J. & Harbour, J. W. For whom the bell tolls: susceptibility to common adult cancers in retinoblastoma survivors. J. Natl Cancer Inst. 96, 342-343 (2004).
184. Horowitz, J. M. et al. Anti-oncogenes and the negative regulation of cell growth. Cold Spring Harb. Symp. Quant. Biol. 53, 843-847 (1988).
185. Delston, R. B. & Harbour, J. W. Rb at the interface between cell cycle and apoptotic decisions. Curr. Mol. Med. 6, 713-718 (2006).
186. Li, W. et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 38, 287-301 (2006).
187. MacGrogan, D. & Bookstein, R. Tumour suppressor genes in prostate cancer. Semin. Cancer Biol. 8, 11-19 (1997).
188. Hugel, A. & Wernert, N. Loss of heterozygosity (LOH), malignancy grade and clonality in microdissected prostate cancer. Br. J. Cancer 79, 551-557 (1999).
189. Abate-Shen, C. & Shen, M. M. Molecular genetics of prostate cancer. Genes Dev. 14, 2410-2434 (2000).
190. Cox, L. A., Chen, G. & Lee, E. Y. Tumor suppressor genes and their roles in breast cancer. Breast Cancer Res. Treat. 32, 19-38 (1994).
191. Bosco, E. E. & Knudsen, E. S. RB in breast cancer: at the crossroads of tumorigenesis and treatment. Cell Cycle 6, 667-671 (2007).
192. Miyamoto, H., Shuin, T., Ikeda, I., Hosaka, M. & Kubota, Y. Loss of heterozygosity at the p53, RB, DCC and APC tumor suppressor gene loci in human bladder cancer. J. Urol. 155, 1444-1447 (1996).
193. Cordon-Cardo, C., Sheinfeld, J. & Dalbagni, G. Genetic studies and molecular markers of bladder cancer. Semin. Surg. Oncol. 13, 319-327 (1997).
194. Mitra, A. P., Datar, R. H. & Cote, R. J. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J. Clin. Oncol. 24, 5552-5564 (2006).
195. Krug, U., Ganser, A. & Koeffler, H. P. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21, 3475-3495 (2002).
196. Beck, Z. et al. Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia. Leuk. Lymphoma 38, 587-597 (2000).
197. Zhu, Y. M., Haynes, A. P., Keith, F. J. & Russell, N. H. Abnormalities of retinoblastoma gene expression in hematological malignancies. Leuk. Lymphoma 18, 61-67 (1995).
198. Jacks, T. et al. Effects of an Rb mutation in the mouse. Nature 359, 295-300 (1992).
199. Honda, S. et al. Human pituitary adenomas infrequently contain inactivation of retinoblastoma 1 gene and activation of cyclin dependent kinase 4 gene. Endocr. J. 50, 309-318 (2003).
200. Wechsler-Reya, R. & Scott, M. P. The developmental biology of brain tumors. Annu. Rev. Neurosci. 24, 385-428 (2001).
201. Hulleman, E. & Helin, K. Molecular mechanisms in gliomagenesis. Adv. Cancer Res. 94, 1-27 (2005).
202. Jenkins, G. J. et al. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br. J. Surg. 89, 824-837 (2002).
203. Lerut, T. & Decker, G. Esophageal cancer. Curr. Opin. Gastroenterol. 15, 364-369 (1999).
204. Zhang, X. et al. Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res. 54, 4177-4182 (1994).
205. Murakami, Y., Hayashi, K., Hirohashi, S. & Sekiya, T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 51, 5520-5525 (1991).
206. Villanueva, A., Newell, P., Chiang, D. Y., Friedman, S. L. & Llovet, J. M. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 27, 55-76 (2007).
207. Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
208. Kowalski, J. et al. Chromosomal abnormalities of adenocarcinoma of the pancreas: identifying early and late changes. Cancer Genet. Cytogenet. 178, 26-35 (2007).
209. Decker, H. J. et al. Cytogenetic and molecular studies of a familial renal cell carcinoma. Cancer Genet. Cytogenet. 63, 25-31 (1992).
210. Sanseverino, F., Torricelli, M., Petraglia, F. & Giordano, A. Role of the retinoblastoma family in gynecological cancer. Cancer Biol. Ther. 2, 636-641 (2003).
211. Moller, M. B. et al. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia 14, 898-904 (2000).
212. Leoncini, L., Bellan, C. & De Falco, G. Retinoblastoma gene family expression in lymphoid tissues. Oncogene 25, 5309-5314 (2006).
213. Juge-Morineau, N., Harousseau, J. L., Amiot, M. & Bataille, R. The retinoblastoma susceptibility gene RB-1 in multiple myeloma. Leuk. Lymphoma 24, 229-237 (1997).
214. DeLellis, R. A. Pathology and genetics of thyroid carcinoma. J. Surg. Oncol. 94, 662-669 (2006).
215. Zheng, L., Wang, L., Ajani, J. & Xie, K. Molecular basis of gastric cancer development and progression. Gastric Cancer 7, 61-77 (2004).
216. Wikenheiser-Brokamp, K. A. Rb family proteins differentially regulate distinct cell lineages during epithelial development. Development 131, 4299-4310 (2004).
217. Maddison, L. A., Sutherland, B. W., Barrios, R. J. & Greenberg, N. M. Conditional deletion of Rb causes early stage prostate cancer. Cancer Res. 64, 6018-6025 (2004).
218. Zhou, Z. et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res. 66, 7889-7898 (2006).
219. Higashitsuji, H. et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nature Med. 6, 96-99 (2000).